For the Inventor, By the Inventor

Enter assignee name

Basel, Switzerland

Basilea Pharmaceutica Ag

USPTO Granted Patents = 72

% Expired Patents = 51.4

CIPO Patents = 6

EPO Patents = 28

Trademarks = 1

Forward Citations = 118

Loading Chart...

Loading Chart...

102 inventors (with patents filed for the assignee):

Felix Bachmann (16 out of 19 patents)

Heidi Alexandra Lane (9 out of 9 patents)

Johannes Laurenz Kellenberger (9 out of 10 patents)

4. Nobuo Shimma (7 out of 35 patents)

5. Jürg Dreier (7 out of 7 patents)

6. Lin Xu (7 out of 9 patents)

7. Franck Hubert Danel (6 out of 6 patents)

8. Martin Eberle (6 out of 21 patents)

9. Alessandro Strebel (6 out of 6 patents)

10. Subho Roy (6 out of 6 patents)

11. Goutam Saha (6 out of 6 patents)

12. Marc Muller (6 out of 16 patents)

13. Patrick Roussel (5 out of 14 patents)

14. Berangere Gaucher (5 out of 5 patents)

15. Eisaku Mizuguchi (5 out of 10 patents)

Core Competencies:

Biomarkers

Macrolides

Furazanobenzimidazoles

Antifungal Agents

Tricyclic Antibiotics

Bicyclic Antibiotics

Combination Therapy

Cephalosporin

Beta-Lactamase Inhibitors

PDE4-Inhibiting Activity

N-Substituted Derivatives

Epoxybutanol Intermediates

72 patents: Sort by Forward Citations

1. 10724072 - Use of phospho-Akt as a biomarker of drug response (2020-07-28),

2. 10656162 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles (2020-05-19),

3. 10590092 - Process for the manufacture of isavuconazole or ravuconazole (2020-03-17),

4. 10222377 - Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles (2019-03-05),

5. 10221206 - Selected macrolides with PDE4-inhibiting activity (2019-03-05),

6. 10067120 - Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles (2018-09-04),

7. 10006078 - Use of phospho-Akt as a biomarker of drug response (2018-06-26),

8. 9995754 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles (2018-06-12),

9. 9970938 - Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles (2018-05-15),

10. 9783508 - Process for the manufacture of isavuconazole or ravuconazole (2017-10-10),

11. 9738676 - Selected macrolides with PDE4-inhibiting activity (2017-08-22),

12. 9511064 - Combination therapy for the treatment of cancer and immunosuppression (2016-12-06),

13. 9476889 - Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles (2016-10-25),

14. 9366682 - Use of stathmin as a biomarker of drug response to furazanobenzimidazoles (2016-06-14),

15. 9346799 - Useful combinations of monobactam antibiotics with beta-lactamase inhibitors (2016-05-24),

Company Overview

Basilea Pharmaceutica AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative pharmaceutical compounds. The company focuses on addressing unmet medical needs through its expertise in various therapeutic areas, particularly in antifungal and antibacterial treatments. Basilea's research encompasses advanced technologies such as biomarkers and combination therapies, with a strong emphasis on macrolides and unique compounds like furazanobenzimidazoles. Its commitment to improving patient outcomes drives its ongoing development efforts in the pharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

72 Patents

#12 in Basel

#217 in Switzerland

#10,396 in the World

Basel, Switzerland

Basilea Pharmaceutica Ag

Forward Citations = 118

102 inventors:

Felix Bachmann (16 out of 19 patents)

Heidi Alexandra Lane (9 out of 9 patents)

Johannes Laurenz Kellenberger (9 out of 10 patents)

4. Nobuo Shimma (7 out of 35 patents)

5. Jürg Dreier (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Basilea Pharmaceutica Ag. Retrieved from https://idiyas.com/company/basilea-pharmaceutica-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…